KLOXXADO ® delivers 8 mg of naloxone hydrochloride per spray in a ready to use nasal spray to reverse the effects of opioid overdose.

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

The spray – which was approved by the FDA in March – has a wholesale acquisition cost of $295 per 28 mg device and costs around $32,400 for a year’s treatment, says ICER.

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...

Hikma Pharmaceuticals (HKMPF) announces the approval of KLOXXADO Nasal Spray 8 mg, by Health Canada for the treatment of known or suspected ...

The oxytocin system – which helps release breast milk and strengthens the bond between mother and baby – may be affected ...

The oxytocin system - which helps release breast milk and strengthens the bond between mother and baby - may be affected ...

Breastfeeding mothers with postnatal depression show disruptions in oxytocin systems, impacting bonding and milk release.

The oxytocin system -- which helps release breast milk and strengthens the bond between mother and baby -- may be affected during breastfeeding in mothers experiencing postnatal depression.